Document is current
Any future updates will be listed below
-
Authors
Andersen, Morten N. http://orcid.org/0000-0003-0820-7789
Andersen, Niels F.
Lauridsen, Kristina L.
Etzerodt, Anders
Sorensen, Boe S.
Abildgaard, Niels
Plesner, Trine
Hokland, Marianne
Møller, Holger J.
- License Information
-
More Information
Article History
Received: 24 March 2020
Accepted: 26 April 2021
First Online: 1 June 2021
Declarations
:
: HJM is a minority shareholder in DeLiver Pharma that holds IP protecting the use of CD163 drug targeting. All other authors declare no conflict of interest.
